You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Gra

    SBC: ASTER LABS, INC.            Topic: NCBDDD

    Abstract In this Phase II SBIR project, ASTER Labs will enhance a hands-free automatic oral hygiene device in the form of a comfortable mouthpiece that was designed and successfully tested and evaluated during a Phase I study for persons with oral hygiene disabilities and their caregivers, and then investigate the device’s efficacy in reducing dental plaque and reducing burden, thereby improving ...

    SBIR Phase II 2019 Department of Health and Human ServicesCenters for Disease Control and Prevention
  2. Discovery of T-type Calcium Channel Antagonists from Multicomponent Reactions and Their Application in Paclitaxel-induced Peripheral Neuropathy

    SBC: Regulonix            Topic: 101

    Summary Abstract Chemotherapy induced peripheral neuropathyCIPNis detected inof cancer patients during all phases of cancerSensory symptoms in the hands and or feettypically in astocking glovepatternare commonand manifested as painnumbnessand or tinglingCIPN can result in chemotherapy dose reduction or discontinuationand can also have long term effects on the quality of lifeThe course of CIPN can ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. IMPACT-Instrument to Measure Pain and Assess Correlation to Treatment. Create a smartphone pupillometry to objectively determine the presence of acute pain, evaluate opioid as the treatment for pain.

    SBC: BENTEN TECHNOLOGIES, INC.            Topic: NIDA

    PROJECT SUMMARY ABSTRACT While patient self report of pain is currently the gold standard of pain measurementaccurate self reports of pain may not be feasible in critically ill patients who are sedated and intubatedunconscious patientsor patients who are unable to verbally communicate their painCurrent research has shown that pupillary dilationPDis a reliable indicator of acute painand that measur ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Targeted Intraceptors for Macular Degeneration

    SBC: Iveena Delivery Systems, Inc.            Topic: NEI

    Project Summary Age-related Macular Degeneration (AMD) is the leading cause of blindness in US. It affects over 25% of the people by the age 80. An estimated 25 million people are afflicted with AMD worldwide. Neovascular or “wet” AMD, which affects 10%–15% of AMD patients, is a rapid form of the disease and progresses to blindness if left untreated. Histopathologically, the disease involves ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. AI-enabled fully automated retinal image-based biomarkers for mild cognitive impairment and neurodegenerative disorders

    SBC: EYENUK, INC.            Topic: NINDS

    AbstractIn this SBIR projectwe present EyeQuantan AI enabled fully automated tool to compute retinal image based biomarkers for mild cognitive impairment and neurodegenerative disordersThe largegrowingand aging population is likely to lead to a dramatic increase in the number of people at risk for dementia and other cognitive disorderswith more thanmillion people expected to be affected byVascular ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a human cellular TBK1 model for drug discovery in ALS

    SBC: Quralis Corporation            Topic: 103

    Program SummaryAmyotrophic lateral sclerosisALSaffects an estimatedindividuals in theUnited States andworldwideThe disease is characterized by loss of motor neurons leadingto loss of muscle control and muscle wastingPatients typically progress from diagnosis todeath inyearsWhile there are two approved therapies to treat ALStheir effectsare limitedThe lack of available treatments for ALS patients r ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Improving treatment options and outcomes in fungal keratitis

    SBC: TranZ Biosciences LLC            Topic: N

    ABSTRACT Fungal keratitisprimarily caused by CandidaFusariumor Aspergillus speciesis a leading cause of blindness among corneal diseasesAmphotericin BAmBremains the gold standard in the treatment of Candida keratitis and is also the fallback option for other corneal fungal infectionsAlthough widely used off label in ocular infectionsophthalmic AmB formulations are not available commerciallyThe com ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting PDGFs for Potential Treatment of Proliferative Vitreoretinopathy

    SBC: APTITUDE MEDICAL SYSTEMS INC            Topic: NEI

    Abstract SignificanceProliferative vitreoretinopathyPVRis a blinding orphan indication that occurs inof patients receiving rhegmatogenous retinal reattachment surgeryand accounts forof all primary surgical failuresPVR is characterized by migration and proliferation of ectopic cells beneath or on the surface of the retinawhich then assemble into a membranecausing retinal traction and detachmentSinc ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels

    SBC: NAVEGA THERAPEUTICS, INC.            Topic: 102

    Project Summary Abstract The goal of this project is to develop a therapeutic product that relieves chemotherapy induced peripheral neuropathyCIPNin a non permanentnon addictive and long lasting manner to improve the quality of life of cancer patientsCurrently more thanmillion Americans andbillion people worldwide suffer from chronic painVoltage gated sodium channels transmit pain signals in nocic ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Telemetric Microsensor for Glaucoma

    SBC: H-CUBED            Topic: NEI

    PROJECT SUMMARY Glaucoma is an optic nerve disease in which there is progressive loss of retinal ganglion cells leading to irreversible loss of vision. It is estimated to affect 2% of the general population. More than 2.3 million Americans are affected with glaucoma and it is estimated to account for nearly $3B in direct medical costs. It is estimated that 4% of Caucasian patients and 8% of Africa ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government